Press release
November 13, 2025
Instil Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Instil Bio, Inc. (TIL)
First patient dosed in Phase 1 clinical trial evaluating AXN-2510/IMM2510 (“’2510”) monotherapy in adult patients with advanced solid tumors DALLAS, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a